AURINIA PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: Election of Directors: Dr. Daniel G. Billen

AURINIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Dr. Daniel Billen”): 33,343,245 for, 43,247,441 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 44% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 38 asset managers below reported 8,592,072 for, 729,012 withheld.

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

Description as filed by funds: Election of Directors: Dr. Brinda Balakrishnan

AURINIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Dr. Brinda Balakrishnan”): 36,406,544 for, 40,184,139 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 47.5% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 8,858,458 for, 382,626 withheld.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: Election of Directors: Dr. David R. W. Jayne

AURINIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Dr. David R.W. Jayne”): 47,961,382 for, 28,672,488 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 63% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 9,227,630 for, 13,454 withheld.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: Election of Directors: Jeffrey A. Bailey

AURINIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mr. Jeffrey A. Bailey”): 38,651,711 for, 37,972,319 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 50.4% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 9,241,084 for.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: Election of Directors: Jill Leversage

AURINIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Ms. Jill Leversage”): 48,882,668 for, 27,741,202 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 9,227,630 for, 13,454 withheld.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: Election of Directors: Dr. Karen Smith

AURINIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Dr. Karen Smith”): 38,979,544 for, 37,644,485 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 50.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 9,241,084 for.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: Election of Directors: Peter Greenleaf

AURINIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mr. Peter Greenleaf”): 36,942,214 for, 39,681,657 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 48.2% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 9,241,084 for.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: Election of Directors: R. Hector MacKay-Dunn

AURINIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mr. R. Hector MacKay-Dunn”): 35,001,819 for, 41,588,866 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 45.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 8,795,826 for, 445,258 withheld.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: Election of Directors: Dr. Robert T. Foster

AURINIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Dr. Robert T. Foster”): 39,405,046 for, 37,218,984 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 51.4% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 9,241,084 for.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: Amendment to Equity Incentive Plan To approve the amendment to the Company's Equity Incentive Plan to increase the maximum number of common shares of the Company reserved for issuance pursuant to the Equity Incentive Plan, as set forth in the Company's Proxy Statement/Circular.

AURINIA PHARMACEUTICALS INC.’s own tally for this item (“Proposal 4: Based upon the following votes, the shareholders did not approve the Company's Amendment to the Equity Incentive Plan.”): 35,700,702 for, 40,481,025 against — failed, per its Form 8-K filed June 14, 2024 (Item 5.07).

Reported outcome: Not approved, in the filing’s own words: “Proposal 4: Based upon the following votes, the shareholders did not approve the Company's Amendment to the Equity Incentive Plan.”
Support: 46.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of AURINIA PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “To approve the amendment to the Company s Equity Incentive Plan to increase the maximum number of common shares of the Company reserved for issuance pursuant to the Equity Incentive Plan, as set forth in the Company s Proxy Statement/Circular.” (7 managers, 761,020 for); “Amendment to Equity Incentive Plan - To approve the amendment to the Company's Equity Incentive Plan to increase the maximum number of common shares of the Company reserved for issuance pursuant to the Equity Incentive Plan, as set forth in the Company's Proxy Statement/Cirular” (3 managers, 78,625 for, 34,509 against).

The 29 asset managers below reported 8,432,730 for, 13,454 against.

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

Description as filed by funds: Advisory Resolution on Executive Compensation To approve, on a non-binding advisory basis, a "say on pay" resolution regarding the Company's executive compensation set forth in the Company's Proxy Statement/Circular.

AURINIA PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: Based upon the following votes, the shareholders did not approve on a non-binding advisory basis, a "say on pay" resolution regarding the Company's executive compensation.”): 30,780,033 for, 45,321,684 against — failed, per its Form 8-K filed June 14, 2024 (Item 5.07).

Reported outcome: Not approved, in the filing’s own words: “Proposal 3: Based upon the following votes, the shareholders did not approve on a non-binding advisory basis, a "say on pay" resolution regarding the Company's executive compensation.”
Support: 40% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of AURINIA PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (5 managers, 489,272 against).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 37 managers: 7,911,703 for, 1,407,985 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 141 managers: 20,520,299 for, 5,847,406 against, 1,140 abstained, 18,935 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Appointment of Auditors Appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the 2025 annual general meeting of shareholders or until a successor its appointed.

AURINIA PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: Based upon the following votes, the shareholders approved the appointment of PricewaterhouseCoopers LLP, Chartered Professional Accountants, as the Company's independent registered public accounting firm unti”): 85,574,567 for, 8,080,642 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Based upon the following votes, the shareholders approved the appointment of PricewaterhouseCoopers LLP, Chartered Professional Accountants, as the Company's independent registered public accounting firm until the annual general meeting of shareholders to be held in 2025 or until a succ…”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 9,319,688 for.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.